China's corruption watchdog on Saturday said it has disciplined more than 80 officials linked to a major vaccine scandal last summer that inflamed public fears over the safety of domestically produced drugs.
Changchun Changsheng Biotechnology -- a major Chinese manufacturer of rabies vaccines -- was slapped with a USD 1.3 billion fine last October after it was found to have fabricated records.
Four officials from the China Food and Drug Administration (CFDA), including a deputy director, have been handed over to prosecutors, the Central Commission for Discipline Inspection said in a statement Saturday.
The brief statement did not say what they were alleged to have done.
The graft watchdog also said it would "seriously deal with" more than 80 other provincial or local officials from multiple government organisations, without offering details.
These officials have already been fired or demoted, it said. Authorities earlier said the faulty rabies vaccines did not enter the market. But the case provoked outrage from customers fed up with recurring product-safety scandals, particularly in the drug sector.
The drug company's chairwoman and 14 employees were arrested after the scandal came to light last July, while more than a dozen national, provincial and local officials were sacked.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
